Gossamer Bio, Inc. 2025 Annual Report: Key Highlights for Investors

Ticker: GOSS
Exchange: Nasdaq Global Select Market
Fiscal Year End: December 31, 2025
Common Shares Outstanding (as of March 10, 2026): 234,696,281
Public Float (as of June 28, 2025): ~\$270.8 million at \$1.23/share

Overview

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for pulmonary, fibrotic, and rare diseases. The company’s lead asset is seralutinib, a potential treatment for pulmonary arterial hypertension (PAH) and other serious lung diseases. Gossamer has also been advancing RT234 for on-demand relief of dyspnea in patients with pulmonary hypertension.

Key Developments in 2025

• Seralutinib Regulatory Path: Gossamer is actively engaging with the U.S. Food and Drug Administration (FDA) to define a regulatory path forward for seralutinib in PAH. The company has completed analyses of the PROSERA dataset and is requesting a Type C meeting with the FDA to discuss the totality of both the PROSERA and earlier TORREY datasets. Investors should note the company anticipates a potential approval decision by the end of 2027, subject to FDA feedback and regulatory review timelines.
• Preparations for NDA Submission: Gossamer is advancing preparations toward a potential New Drug Application (NDA) submission for seralutinib. Timing of any FDA action—and thus potential commercialization—remains dependent on the outcome of ongoing interactions with the FDA and the regulatory process.
• SERANATA Trial Update: The company has paused enrollment in the SERANATA trial, which is evaluating seralutinib in fibrotic lung disease (including pulmonary hypertension associated with interstitial lung disease, or PH-ILD). This pause is intended to support disciplined resource allocation and allow time to consider the implications of PROSERA data as Gossamer engages with regulators. Importantly, Gossamer notes continued belief in seralutinib’s potential in fibrotic lung diseases, particularly based on positive findings in the connective tissue disease-associated PAH (CTD-APAH) subgroup within PROSERA.
• Capital Structure and Financial Strategy: The company is evaluating a range of alternatives to optimize its capital structure, including potential actions related to its outstanding convertible notes. Gossamer may seek to raise additional capital via equity offerings, debt financings, or other sources to support strategic priorities and ensure sufficient runway for seralutinib development and other pipeline activities.
• RT234 Program: Under its option agreement with Respira Therapeutics, Gossamer is advancing RT234 in a capital-efficient manner. Activities are currently limited to foundational manufacturing and device readiness, with further development contingent on resource prioritization and the company’s focus on seralutinib.

Additional Investor Information

• SEC Filings and Compliance: Gossamer confirms its status as a non-accelerated filer and a smaller reporting company, and has filed all required reports in the past 12 months. It is not an emerging growth company and has not been subject to ICFR auditor attestation under Section 404(b) of Sarbanes-Oxley.
• Error Corrections & Restatements: There were no error corrections or restatements requiring recovery analysis of incentive-based compensation.
• Shell Company Status: Gossamer is not a shell company.
• Proxy Statement Incorporation: Certain sections of the 2026 proxy statement, to be filed within 120 days, will be incorporated by reference into Part III of the 10-K.

Forward-Looking Statements and Risk Factors

The report contains forward-looking statements regarding Gossamer’s future results, regulatory plans, and anticipated timelines. These statements are subject to risks and uncertainties that may cause actual results to differ materially, including but not limited to regulatory outcomes, clinical data interpretation, capital markets conditions, and competitive dynamics. Investors are urged to review the “Risk Factors” section of the 10-K for a comprehensive list of potential risks impacting Gossamer’s business.

Potential Share Price Drivers

• Regulatory Milestones for Seralutinib: Upcoming FDA interactions, feedback on the regulatory path, and any progress toward NDA submission or approval could significantly impact Gossamer’s valuation.
• Pipeline Progress or Setbacks: Updates on the paused SERANATA trial, new data releases, or expansion into additional indications could serve as catalysts.
• Capital Structure Actions: Any material changes to outstanding convertible notes, new financings, or strategic partnerships could affect the share price.
• RT234 Development: Progress in the RT234 program, even in a capital-efficient mode, may provide upside if partnered or advanced further.

Summary for Shareholders

Key Points:

• Gossamer’s lead asset, seralutinib, is at a critical regulatory juncture, with potential NDA submission and FDA approval as key upcoming milestones.
• Enrollment in the SERANATA trial is paused to conserve capital, but seralutinib retains promise in fibrotic lung disease based on subgroup findings.
• The company is actively managing its capital structure and may undertake additional financings, which could impact dilution and shareholder value.
• RT234 continues under a risk-managed development plan, preserving resources for core priorities.
• Investors should closely monitor upcoming FDA feedback, regulatory filings, and any capital structure changes as they are likely to be material for GOSS share valuation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties described in Gossamer Bio’s filings with the SEC. Investors should review the full 10-K and consult their financial advisors before making investment decisions.

View Gossamer Bio, Inc. Historical chart here